A5086973347- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- Cancer, Lipids, and Metabolism
- Hepatitis B Virus Studies
- Cancer Mechanisms and Therapy
- Liver Diseases and Immunity
- Hepatitis C virus research
- Viral-associated cancers and disorders
- Pancreatic and Hepatic Oncology Research
- Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Renal cell carcinoma treatment
- MRI in cancer diagnosis
- Cancer Genomics and Diagnostics
- Medical Imaging and Pathology Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Liver physiology and pathology
- Liver Disease and Transplantation
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Bone and Joint Diseases
- Organ Transplantation Techniques and Outcomes
University of Amsterdam
2018-2021
Amsterdam University Medical Centers
2018-2021
Cancer Center Amsterdam
2018-2020
Amsterdam UMC Location University of Amsterdam
2017-2018
Erasmus MC
2017
The heterogeneity of intermediate-stage hepatocellular carcinoma (HCC) and the widespread use transarterial chemoembolization (TACE) outside recommended guidelines have encouraged development scoring systems that predict patient survival. aim this study was to build validate statistical models offer individualized survival prediction using response TACE as a variable.Clinically relevant baseline parameters were collected for 4,621 patients with HCC treated at 19 centers in 11 countries. In...
Previous studies have suggested body composition as a predictor of sorafenib toxicity and outcome in patients with advanced hepatocellular carcinoma (HCC). Large on the impact parameters European HCC are lacking. Our aim was to validate prognostic value Dutch treated sorafenib.A retrospective analysis performed cohort at two tertiary referral centers between 2007 2016. Body (adipose skeletal muscle tissue) measured baseline by computed tomography (CT). Low mass (SMM) density were defined...
The 'Prediction Of Survival in Advanced Sorafenib-treated HCC' (PROSASH) model addressed the heterogeneous survival of patients with hepatocellular carcinoma (HCC) treated sorafenib clinical trials but requires validation daily practice. This study aimed to validate, compare and optimize this for prediction.Patients HCC at five tertiary European centres were retrospectively staged according PROSASH model. In addition, optimized PROSASH-II was developed using data four (training set) tested...
Abstract Background Liver transplantation (LT) has been performed in a select group of patients presenting with unresectable or primary sclerosing cholangitis (PSC)-associated perihilar cholangiocarcinoma (pCCA) the Mayo Clinic reported 5-year overall survival (OS) 53% on intention-to-treat analysis. The objective this study was to estimate eligibility for LT cohort pCCA two tertiary referral centers. Methods Patients diagnosed between 2002 and 2014 were included from centers Netherlands....
Radioembolization is increasingly used as a bridge to resection (i.e., radiation lobectomy). It combines ipsilateral tumor control with the induction of contralateral hypertrophy facilitate lobar resection. The aim this pilot study was investigate complementary value hepatobiliary scintigraphy (HBS) before and after radioembolization in assessment future remnant liver. <b>Methods:</b> Consecutive patients liver tumors who underwent HBS <sup>90</sup>Y were included. Regional...
Abstract Lessons Learned Recruitment of patients with advanced hepatocellular carcinoma and Child-Pugh B for sorafenib treatment additional pharmacokinetic studies is challenging. Patients liver cirrhosis have high rates cirrhosis-related adverse events. Background Few data are available on the pharmacokinetics (PK) in (HCC) cirrhosis. This study aimed to explore PK its relationship efficacy toxicity these patients. Methods HCC B7-8 function were prospectively recruited at a tertiary center....
Transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (HCC) is often repeated until unTACEable progression (UTP) occurs. There little data on the various reasons stopping TACE and its consequences subsequent treatment survival.To assess impact of UTP survival treatments.Consecutive HCC patients who underwent between 2003 2016 were analyzed retrospectively reason discontinuation. was defined according to EASL guidelines, considering radiological pattern...
Background: Sorafenib for advanced hepatocellular carcinoma (HCC) is dose adjusted by toxicity. Preliminary studies have suggested an association between plasma concentrations of sorafenib and its main metabolite (M2) clinical outcomes. This study aimed to validate these findings establish target values trough concentrations.Methods: Patients with HCC were prospectively recruited within a multicenter phase II (SORAMIC). blood samples available at level included this pharmacokinetic (PK)...
Survival outcomes of patients with hepatocellular carcinoma (HCC) treated transarterial chemoembolization (TACE) are heterogeneous. Measuring the apparent diffusion coefficient (ADC) using diffusion-weighted imaging (DWI) may improve overall survival prediction.To assess value measuring ADC before and after TACE in predicting survival.A retrospective analysis was performed HCC at a tertiary referral center between 2008 2017. The values changes (ΔADC) lesions (≥ 1 cm) liver parenchyma were...
Background: Upon FDA/EMEA registration for hepatocellular carcinoma (HCC), sorafenib received a broader therapeutic indication than the eligibility criteria of landmark SHARP trial. This allowed treatment non-eligible patients in daily clinical practice.Aim: To assess efficacy and safety eligible patients, determine validity current as described by FDA/EMEA.Patients methods: Consecutive treated with advanced HCC at two Dutch tertiary referral centers between 2007 2016 were analyzed...
Background Studies assessing the impact of selective internal radiation therapy (SIRT) on regional liver function in patients with hepatocellular carcinoma (HCC) are sparse. This study assessed changes total and using hepatobiliary scintigraphy (HBS) investigated utility HBS to predict post-SIRT dysfunction. Methods Patients treated SIRT for HCC between 2011 2019, underwent 99m Tc-mebrofenin single-photon emission computed tomography/computed tomography (SPECT/CT) before 6 weeks after SIRT....
Selective internal radiation therapy (SIRT) is used as a treatment for hepatocellular carcinoma (HCC). The aim of this study was to assess long-term liver-related complications SIRT in patients who had not developed radioembolization-induced liver disease (REILD). primary outcome the percentage without REILD that Child-Pugh (CP) ≥ B7 decompensation after SIRT. secondary outcomes were overall survival (OS) and tumor response. These data compared with matched cohort treated sorafenib....
Introduction Early treatment of acute hepatitis C virus (HCV) infection with interferon alfa monotherapy is highly effective but associated frequent unfavorable side effects. There no fully published study yet exploring the safety, efficacy and required duration interferon-free monoinfection. Preliminary reports suggested that ledipasvir/sofosbuvir therapy in relapses were reported HIV-coinfected patients after 6 weeks treatment. Aims & Methods The German HepNet Acute HCV IV Study was...